Venous thromboembolic events following cytoreductive surgery for lower gastrointestinal neoplasia

被引:0
作者
Guirgis, Mina [1 ,2 ]
Keelan, Simon [1 ,2 ]
McEntee, Philip [1 ,2 ]
Han, Margaret [1 ,2 ]
Moroz, Paul [1 ,2 ,3 ,4 ]
机构
[1] Joondalup Hlth Campus, Dept Gen Surg, Perth, WA, Australia
[2] Corner Grant Blvd & Shenton Ave, Joondalup, WA 6027, Australia
[3] Joondalup Hlth Campus, Western Australian Peritonect Serv, Perth, WA, Australia
[4] Joondalup Private Hosp, Specialist Med Ctr East, Suite 24-26,Level 2,60 Shenton Ave, Joondalup, WA 6027, Australia
来源
SURGERY IN PRACTICE AND SCIENCE | 2024年 / 18卷
关键词
Cytoreduction surgical procedures; Appendiceal neoplasms; Pseudomyxoma peritonei; Colorectal cancer; Thromboembolism; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; BLOOD-TRANSFUSION; PROPHYLAXIS; CANCER; PERITONECTOMY; COMPLICATIONS; MULTICENTER; MANAGEMENT; MORBIDITY; MORTALITY;
D O I
10.1016/j.sipas.2024.100257
中图分类号
R61 [外科手术学];
学科分类号
摘要
Introduction: Cytoreductive surgery (CRS) and intraperitoneal chemotherapy (IPC) represent a high-risk for venous thromboembolism (VTE) due to malignancy, prolonged surgery and immobility. We investigated the incidence of and risk factors for VTE following CRS/IPC. Materials and methods: Data was analysed on 130 CRS/IPC performed over a 6-year period at a single centre, the Western Australian Peritonectomy Service (WAPS), on lower gastrointestinal neoplasia: pseudomyxoma peritoneii (PMP), colorectal cancer (CRC) and appendix cancer (AC). Data was analysed by univariate and multivariate logistic regression to identify risk factors for VTE. Results: 31 patients (24%) experienced a VTE. The percentages of VTE among patients with PMP (n = 50), CRC (n = 53) and AC (n = 27) were 36%, 17% and 15% respectively. 60% of these cases were asymptomatic. The odds of VTE were higher for PMP patients than in patients with a other histopathology (OR=2.9, p = 0.01). Other significant risk factors for VTE on univariate analysis were PCI (OR=1.07, p = 0.001), pelvic dissection (OR=5.52, p = 0.001) and operation time (OR=1.36, p = 0.001). Conclusion: This study demonstrates high rates of VTE in patients undergoing CRS/IPC. Patients with PMP have a three-fold higher risk of VTE compared to other malignancies (CRC+AC). As most VTE cases were asymptomatic, aggressive early investigation and intervention is indicated for patients undergoing CRS/IPC.
引用
收藏
页数:5
相关论文
共 21 条
  • [1] A clinical outcome-based prospective study on venous thromboembolism after cancer surgery -: The @RISTOS project
    Agnelli, G
    Bolis, G
    Capussotti, L
    Scarpa, RM
    Tonelli, F
    Bonizzoni, E
    Moia, M
    Parazzini, F
    Rossi, R
    Sonaglia, F
    Valarani, B
    Bianchini, C
    Gussoni, G
    Andreoni, B
    Biffi, R
    Cenciarelli, S
    Capussotti, L
    Calgaro, M
    Polastri, R
    Zorzi, D
    Mazzini, G
    Tubaro, A
    Perna, R
    Vicentini, C
    Montemurro, S
    Caliandro, C
    Ruggeri, E
    Gennari, L
    Brocchi, A
    Quagliuolo, V
    Scarpa, RM
    Ragni, F
    Conti, G
    Cretarola, E
    Pagliarulo, A
    D'Achille, G
    Bartoli, A
    Bussotti, C
    Ricci, E
    Servoli, A
    Carrieri, G
    Corvasce, T
    Disabato, G
    Moretti, R
    Bencini, L
    Cantafio, S
    Scatizzi, M
    Scambia, G
    Foti, E
    Frigerio, L
    [J]. ANNALS OF SURGERY, 2006, 243 (01) : 89 - 95
  • [2] Low molecular weight heparin versus unfractionated heparin for perioperative thromboprophylaxis in patients with cancer
    Akl, Elie A.
    Kahale, Lara
    Sperati, Francesca
    Neumann, Ignacio
    Labedi, Nawman
    Terrenato, Irene
    Barba, Maddalena
    Sempos, Elena V.
    Muti, Paola
    Cook, Deborah
    Schuenemann, Holger
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2014, (06):
  • [3] Morbidity and Mortality of Cytoreduction with Intraperitoneal Chemotherapy: Outcomes from the ACS NSQIP Database
    Bartlett, Edmund K.
    Meise, Chelsey
    Roses, Robert E.
    Fraker, Douglas L.
    Kelz, Rachel R.
    Karakousis, Giorgos C.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (05) : 1494 - 1500
  • [4] A Novel Tool for Predicting Major Complications After Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy
    Baumgartner, Joel M.
    Kwong, Thomas G.
    Ma, Grace L.
    Messer, Karen
    Kelly, Kaitlyn J.
    Lowy, Andrew M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2016, 23 (05) : 1609 - 1617
  • [5] Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer.
    Bergqvist, D
    Agnelli, G
    Cohen, AT
    Eldor, A
    Nilsson, PE
    Le Moigne-Amrani, A
    Dietrich-Neto, F
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (13) : 975 - 980
  • [6] A contemporary analysis of morbidity and outcomes in cytoreduction/ hyperthermic intraperitoneal chemoperfusion
    Haslinger, Michelle
    Francescutti, Valerie
    Attwood, Kristopher
    McCart, Judith Andrea
    Fakih, Marwan
    Kane, John M., III
    Skitzki, Joseph J.
    [J]. CANCER MEDICINE, 2013, 2 (03): : 334 - 342
  • [7] Jacquet P, 1996, Cancer Treat Res, V82, P359
  • [8] Jacquet P, 1996, J EXP CLIN CANC RES, V15, P49
  • [9] Incidence, Risk Factors, and Prevention Strategies for Venous Thromboembolism after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Khan, Sohini
    Kelly, Kaitlyn J.
    Veerapong, Jula
    Lowy, Andrew M.
    Baumgartner, Joel M.
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2019, 26 (07) : 2276 - 2284
  • [10] Lanuke K, 2009, CAN J SURG, V52, P18